The Role of Risk Factors in the Development of Atherosclerosis

REFERENCES

• Dawber TR, Kannel WB. The Framingham Study. An epidemiological approach to coronary heart disease. Circulation 1966; 34(4): 553–555.
   Google Scholar
• Expert Panel on Detection, Evaluation and Treatment of High Blood Pressure Cholesterol in Adults. NCEP: second report on the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol (Adult Treatment Panel II). Circulation 1994; 89: 132901445.
   Google Scholar
• Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1937–1847.
   Google Scholar
• Grundy SM, Pasternak R, Greenland P, et al. Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations. A Statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology. Circulation 1999; 100: 1481–1492.
   Google Scholar
• Glanz SA, Parmley WW. Passive and active smoking. A problem for adults. Circulation 1996; 94: 596–598.
   Google Scholar
• Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med 1992; 326(21): 1406–1416.
   Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Relations between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med 1986; 15(3): 254–273.
   Google Scholar
• Doll R, Peto R. Mortality in relation to smoking: 20 years observation on male British doctors. Br Med J 1976; 2: 1525–1536.
   Google Scholar
• Negri E, Franzosi MG, La Vecchia C, et al. Tar yield of cigarettes and risk of acute myocardial infarction. GISSI-EFRIM Investigators. Br Med J 1993; 306(6892): 15671570.
   Google Scholar
• Fuster V, Gotto AM, Libby P, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Patho-genesis of coronary disease: the biologic role of risk factors. J Am Coll Cardiol 1996; 27(5): 964–976.
   Google Scholar
• Glanz SA, Parmley WW. Passive smoking and heart disease: Mechanisms and risk. JAMA 1995; 273: 1047–1053.
   Google Scholar
• Ockene JK, Kuller LH, Svendsen KH, et al. The relationship of smoking cessation to coronary heart disease and lung cancer in the Multiple Risk Factor Intervention Trial (MRFIT). Am J Public Health 1990; 80(8): 954–958.
   Google Scholar
• Rosenberg L, Kaufman D, Helmrich S, et al. The risk of myocardial infraction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 315: 1511–1514.
   Google Scholar
• Abbott RD, Wilson PWF, Kannel WB, et al. High density lipoprotein cholesterol, total cholesterol and myocardial infarction: The Framingham Study. Arteriosclerosis 1988; 8: 207–211.
   Google Scholar
• Anonymous. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269(23): 3015–23.
   Google Scholar
• Buja LM, Kita T, Goldstein JL, et al. Cellular pathology of progressive atherosclerosis in the WHHL rabbit. An animal model of familial hypercholesterolemia. Arteriosclerosis 1983; 3(1): 87–101.
   Google Scholar
• Kawaguchi A, Miyatake K, Yutani C, et al. Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. Am Heart J 1999; 137(3): 410–418.
   Google Scholar
• Brown BG, Zhao Xg, Sacco DE, et al. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. [Review] [85 refs] Circulation 1993; 87(6): 1781–1791.
   Google Scholar
• Anonymous. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383–1389.
   Google Scholar
• Shepard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307.
   Google Scholar
• Goldburt U, Holtzman E, Neufel HN. Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. Br Med J 1985; 290: 12391243.
   Google Scholar
• Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: Framingham study. JAMA 1986; 256: 2835–2838.
   Google Scholar
• Burnett JR, Law AJ, Yeong ML, et al. Severe aortic stenosis and atherosclerosis in a young man with Tangier disease. Am J Cardiol 1994; 73(12): 953–925.
   Google Scholar
• Matthews KA, Meilahn E, Kuller LH, et al. Menopause and risk factors for coronary heart disease [see comments]. N Engl J Med 1989; 321(10): 641–646.
   Google Scholar
• Fruchart JC, De Geteire C, Delfly B, et al. Apolipoprotein A-I containing particles and reverse cholesterol transport: evidence for connection between cholesterol efflux and atherosclerosis risk. Atherosclerosis 1994; 110 (Suppl): S35-39.
   Google Scholar
• Bonnefont-Rousselot D, Therond P, Beaudeux JL, et al. High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis. Clinical Chemistry and Laboratory Medicine 1999; 37(10): 939–948.
   Google Scholar
• Williams PT, Wood PD, Haskell WL, et al. The effects of running mileage and duration on plasma lipoprotein levels. JAMA 1982; 247: 2674–2679.
   Google Scholar
• Woods PD, Stefanick ML, Dreon DM, et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 1988; 319: 1173–1179.
   Google Scholar
• Eagles CJ, Martin U, Non-pharmacological modification of cardiac risk factors. Part III. Smoking cessation and alcohol consumption. J Clin Pharmacy Therapeutics 1998; 23: 19.
   Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341(6): 410–418.
   Google Scholar
• Grover SA, Palmer CS, Coupal L. Serum lipid screening to identify high-risk individuals for coronary death: the results of the lipid research clinics prevalence cohort. Arch Intern Med 1994; 154: 679–684.
   Google Scholar
• Keys A, Menotti A, Aravanis C, et al. The seven countries study: 2,289 deaths in 15 years. Preventive Medicine 1984; 13(2): 141–154.
   Google Scholar
• Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Archives of Internal Medicine 1902; 152(1): 56–64.
   Google Scholar
• Kannel WB, Wolf PA, Garrison RJ: Section 34: Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurement: Framingham Heart Study, 30 year follow-up. Springfield, National Technical Information Service 1987, 1–459.
   Google Scholar
• Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245–1249.
   Google Scholar
• Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med 1991; 325(14): 986–90.
   Google Scholar
• Devereux RB, Roman MJ. Inter-relationships between hypertension, left ventricular hypertrophy and coronary heart disease. J Hypertens 1993: 11 (Suppl 4): S3–S9.
   Google Scholar
• Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risk. Arch Intern Med 1993; 153: 598–615.
   Google Scholar
• Roberts WC. Blood lipid levels and antihypertensive therapy. Am J Cardiol 1987; 60: 33E-35E.
   Google Scholar
• Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59(8): 750–755.
   Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234.
   Google Scholar
• Mietinen H, Lehto S, Slomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group. Diabetes Care 1998; 21: 69–75.
   Google Scholar
• Valmadrid CT, Klein R, Moss Se, et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Int Med 2000; 160(8): 1093–1100.
   Google Scholar
• Hogikyan RV, Galecki AT, Pitt B, et al. Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity. J Clin Endocrinol Metabol 1998; 83(6): 1946–1952.
   Google Scholar
• Hempel A, Maasch C, Heintze U, et al. High glucose concentrations and increase endothelial cell permeability via activation of protein kinase C alpha. Circulation Res 1997; 81: 363–371.
   Google Scholar
• Anon. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977–986.
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Insulin blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
   Google Scholar
• Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905–910.
   Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207–223.
   Google Scholar
• Miller NE: Association of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113: 589–97.
   Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–9.
   Google Scholar
• Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986, 256: 2835–8.
   Google Scholar
• Crouse J, Parks J, Schey H, et al. Studies of low density lipoprotein molecular weight in human beings with coronary heart disease. J Lipid Res 1985; 26: 566–74.
   Google Scholar
• Austin M, King M-C, Vranizan K, et al. The atherogenic lipoprotein phenotype [ALP]; a proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495–506.
   Google Scholar
• Coresh J, Kwiterovich PJ, Smith H, et al. Association of plasma triglyceride and LDL particle diameter, density and chemical composition with premature coronary artery disease in men and women. J Lipid Res 1993; 34: 1687–97.
   Google Scholar
• Capell WH, Zambon A, Austin MA, et al. Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. Arterioscler Thromb Vasc Biol 1996; 16: 1040–6.
   Google Scholar
• Sniderman AD, Zhang X-J, Cianflone K. Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm. Atherosclerosis 2000; 148: 215–29.
   Google Scholar
• McNamara J, Jenner J, Li Z, et al. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 1992; 12: 1284–90.
   Google Scholar
• Rainwater DL. Electrophoretic separation of LDL and HDL subclasses. In: Ordovas JM, editor. Methods in Molecular Biology. Lipoprotein Protocols. Totowa: Humana Press, 1998: 137–151.
   Google Scholar
• Freedman DS, Otvos JD, Jeyarajah EJ, et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 1046–53.
   Google Scholar
• Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81(4A): 18B-25B.
   Google Scholar
• Superko RH Beyond cholesterol reduction. Circulation 1996; 94: 2351–2360.
   Google Scholar
• Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211–228.
   Google Scholar
• Barter PJ, Rye KA. High-density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121: 1–12.
   Google Scholar
• Mechanisms of HDL Antiatherogenicity.
   Google Scholar
• Williams PT, Krauss RM, Vranizan KM, et al. Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfraction in men and women. Arterioscler Thromb 1992; 12: 332–340.
   Google Scholar
• Williams PT, Vranizan KM, Austin MA, et al. Associations of age, adiposity, alcohol intake, menstrual status, and estrogen therapy with high-density lipoprotein subclasses. Arterioscler Thromb 1993; 13: 1654–61.
   Google Scholar
• Johansson J, Carlson LA, Landou C, et al. High-density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991; 11: 174–182.
   Google Scholar
• Drexel H, Aman FW, Rentsch K, et al. Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol 1992; 70: 436–440.
   Google Scholar
• Parra HJ, Mezdour H, Ghalim N, et al. Differential immunoassay on ready-to-use plates for human Lp AI lipoprotein particles. Clin Chem 1990; 36: 1431–5.
   Google Scholar
• Fruchart JC, Ailhaud G, Bard JM. Heterogeneity of high density lipoprotein particles. Circulation 1993; 87 (4 Suppl): III22-7.
   Google Scholar
• Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem 1984; 259: 12201–12209.
   Google Scholar
• Contiero E, Ferrari R, Vaselli GM, et al. Quantification of apolipoprotein AI-containing lipoprotein particles in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998; 39: 201–209.
   Google Scholar
• O'Brien T, Nguyen TT, Hallaway BJ, et al. HDL subparticles and coronary artery disease in NIDDM. Atherosclerosis 1996; 121: 285–91.
   Google Scholar
• Luc G, Parra HJ, Zylberg G, et al. Plasma concentrations of apolipoprotein A-I containing particles in normolipidaemic young men. Eur J Clin Invest 1991; 21: 118–122.
   Google Scholar
• Glomset JA. The plasma lecithin: cholesterol acyltransferase reaction. J Lipid Res 1968; 9: 155–167.
   Google Scholar
• Francone OL, Fielding CJ, Fielding PE. Distribution of cell-derived cholesterol among plasma lipoproteins: a comparison of three techniques. J Lipid Res 1990; 31: 2195–200.
   Google Scholar
• Barter PJ, Hopkins GJ, Gorjatschko L. Lipoprotein substrates for plasma cholesterol esterification. Influence of particle size and composition of the high density lipoprotein subfraction 3. Atherosclerosis 1985; 58: 97–107.
   Google Scholar
• Dobia_ova M, Stribrna J, Sparks DL, et al. Cholesterol esterification rates in very low density lipoprotein and low density lipoprotein-depleted plasma: relation to high-density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. Arterioscler Thromb 1991; 11: 64–70.
   Google Scholar
• Dobia_ova M, Stribrna J, Pritchard PH, et al. Cholesterol esterification rate in plasma depleted of very low and low-density lipoprotein is controlled by the proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle aged and septuagenarian men. J Lipid Res 1992; 33: 1411–1418.
   Google Scholar
• Ohta T, Saku K, Takata K, et al. Fractional esterification rate of cholesterol in high density lipoprotein and HDL in patients with coronary heart disease. Atherosclerosis 1997; 1352): 205–212.
   Google Scholar
• Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease, documented by angiography. Circulation 1986; 74: 758–765.
   Google Scholar
• Morrisett JD.The role of lipoprotein[a] in atherosclerosis. Curr Atheroscler Rep 2000; 2: 243–250.
   Google Scholar
• Lundstam U, Hurt-Camejo E, Olsson G, et al. Proteoglycans contribution on association of Lp(a) and LDL with smooth muscle cell extracellular matrix. Arterioscler Thromb Vasc Biol 1999; 19: 1162–1167.
   Google Scholar
• Bdeir K, Cane W, Canziani G, et al. Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 1999; 94: 2007–2019.
   Google Scholar
• Souolat T, Loyau S, Baudouin V, et al. Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin: a study with individual plasmas presenting natural variations of Lp(a). Thromb Haemost 1999; 82: 121–127.
   Google Scholar
• Dangas G, Ambrose JA, D'Agate DJ. Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease. Am J Cardiol 1999; 83: 583–585.
   Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289–1298.
   Google Scholar
• Cremer P, Nagel D, Labrot B, et al. Lipoprotein(a) as predictor of myocardial infarction in comparison with fibrinogen, LDL cholesterol and other risk factors.: results from prospective Gottingen Risk Incidence and Prevalence Study. Eur J Clin Invest 1994; 24: 444–453.
   Google Scholar
• Bostom, Gagnon DR, Cupples, et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994; 90: 1688–1695.
   Google Scholar
• Budde T, Fechtrup C, Bosenberg E, et al. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb 1994; 14: 1730–1436.
   Google Scholar
• Kronenberg F, Kronenberg FM, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck Study. Circulation 1999; 100: 1154–1160.
   Google Scholar
• Cantin B, Gagnon F, Moorjani S, et al. Is Lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol1998; 31: 519–525.
   Google Scholar
• Miller Bass K, Newschaffer CJ, Klag MJ, et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153: 2209–2216.
   Google Scholar
• Salomaa V, Rasi V, Pekkanen J, et al. Haemostatic factors and prevalent coronary heart disease; the FINRISK Haemostasis Study. Eur Heart J 1994; 15: 1293–1299.
   Google Scholar
• Tate JR, Berg K, Couderc R, et al. International federation of clinical chemistry and laboratory medicine (IFCC) standardization project for the measurement of Llipoprotein (a). Clin Chem Lab Med 1999; 37: 949–958.
   Google Scholar
• Marcovina SM, Koschinsky M, Rifai N, Warwick GR, Dominiczak MH, Eds. Handbook of Lipoprotein Testing, 2nd ed, AACC Press, 2000 p. 345–386.
   Google Scholar
• Lonn E, Genest J Jr, Hankley G, et al. Homocysteine and cardiovascular disease: a critical review of the epidemiological evidence. Ann Intern Med 1999; 131(5): 363–375.
   Google Scholar
• Christen WG, Ridker PM. Blood levels of homocysteine and atherosclerotic vascular disease. Curr Atheroscler Rep 2000; 2: 194–199.
   Google Scholar
• Graham IM, O'Callaghan P. The role of folic acid in the prevention of cardiovascular disease. Curr Opin Lipidol 2000; 11: 577–587.
   Google Scholar
• Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873–2879.
   Google Scholar
• Bloom HJ, Engelen DP, Boers GH, et al. Lipid peroxidation in homocysteinemia. J Inherit Metab Dis 1992; 15: 419–422.
   Google Scholar
• Hackam DG, Peterson JC, Spence D. What level of plasma homocysteine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocysteine levels above and below 14 |imol/L.
   Google Scholar
• Vermeulen EGJ, Stehouwer CDA, Twisk JWR, et al. Effect on homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000; 355: 517–522.
   Google Scholar
• Ross R, Glomset J, Harker L. Response to injury and atherogenesis. 1977; Am J Path 86(3): 675–84.
   Google Scholar
• Benitez RM. Atherosclerosis: an infectious disease? [Review] Hospital Practice (Office Edition). 1999; 34(9): 79-82, 85-6, 89-90.
   Google Scholar
• Sullivan GW, Sarembock IJ, Linden J. The role of inflammation in vascular diseases. [Review] J Leukocyte Biol 2000; 67(5): 591–602.
   Google Scholar
• Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. [Review] Curr Opin Lipidol 1998; 9(5): 471–4.
   Google Scholar
• Ross R. Atherosclerosis—an inflammatory disease. [Review] New Engl J Med 1999; 340(2): 115–26.
   Google Scholar
• Byrne G, Kalayoglu MV. Chlamydia pneumoniae and atherosclerosis: links to the disease process. Am Heart J 1999; 138(5 Pt 2): S488-90.
   Google Scholar
• Kuvin JT, Kimmelstiel CD. Infectious causes of atherosclerosis. [Review] Am Heart J 1999; 137(2): 216–26.
   Google Scholar
• Orfila JJ. Seroepidemiological evidence for an association between Chlamydia pneumoniae and atherosclerosis. [Review] Atherosclerosis 1998; 140 (Suppl 1): S11–5.
   Google Scholar
• Mayr M, Kiechl S, Willeit J, et al. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102(8): 833–9.
   Google Scholar
• Fagerberg B, Gnarpe J, Gnarpe H, et al. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. Stroke 1999; 30(2): 299305.
   Google Scholar
• Ossewaarde JM, Feskens EJ, De Vries A, et al. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytome-galovirus are not. Epidemiol Infect 1998; 120(1): 93–9.
   Google Scholar
• Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103(8): 1064–1070.
   Google Scholar
• Zhu J, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol 2000; 85(2): 140–6.
   Google Scholar
• Zhu J, Nieto FJ, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001; 103: 45–51.
   Google Scholar
• Ayyobi A, Chan S. Pathogenesis of atherosclerosis. What is the culprit; Infection or inflammation? Perspect Cardiol 2000; Nov/Dec: 38–45.
   Google Scholar
• Leinonen SP, Mattila M, Ekman K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2(8618): 983–6.
   Google Scholar
• Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Annal Intern Med 1992; 116(4): 273–8.
   Google Scholar
• Melnick SL, Shahar E, Folsom AR, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med 1993; 95(5): 499–504.
   Google Scholar
• Thom DH, Wang SP, Grayston JT, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991; 11(3): 547–51.
   Google Scholar
• Thom DH, Grayston JT, Siscovick DS, et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268(1): 68–72.
   Google Scholar
• Altman R, Rouvier J, Scazziota A, et al. Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease. Clin Cardiol 1999; 22(2): 85–90.
   Google Scholar
• Campbell LA, Blessing E, Rosenfeld M, et al. Mouse models of C. pneumoniae infection and atherosclerosis. [Review] J Infect Dis 2000; 181 (Suppl 3): S508-13.
   Google Scholar
• Moazed TC, Kuo C, Grayston JT, et al. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997; 175(4): 883–90.
   Google Scholar
• Muhlestein JB. Chlamydia pneumoniae-induced atherosclerosis in a rabbit model. [Review] J Infect Dis 2000; 181 (Suppl 3): S505–7.
   Google Scholar
• Horvath R, Cerny J, Benedik J Jr, et al. The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis. J Clin Virol 2000; 16(1): 17–24.
   Google Scholar
• Bartels C, Maass M, Bein G, et al. Detection of Chlamydia pneumoniae but not cytome-galovirus in occluded saphenous vein coronary artery bypass grafts. Circulation 1999; 99(7): 879–82.
   Google Scholar
• Daus H, Ozbek C, Saage D, et al. Lack of evidence for a pathogenic role of Chlamydia pneumoniae and cytomegalovirus infection in coronary atheroma formation. Cardiology 1998; 90(2): 83–8.
   Google Scholar
• Adam E, Melnick JL, DeBakey ME. Cytomegalovirus infection and atherosclerosis. [Review] Central European Journal of Public Health 1997; 5(3): 99–106.
   Google Scholar
• Nieto FJ, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996; 94(5): 922–7.
   Google Scholar
• Sorlie PD. Nieto FJ. Adam E. Folsom AR. Shahar E. Massing M. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arch Intern Med 2000; 160(13): 2027–32.
   Google Scholar
• Rothenberger D, Hoffmeister A, Bode G, et al. Cytomegalovirus infection and coronary heart disease; results of a German case-control study. J Infect Dis 1999; 179: 690–2.
   Google Scholar
• Danesh J, Wong Y, Ward M, et al. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease. Heart 1999; 81(3): 245–7.
   Google Scholar
• Adam E, Melnick JL, Probtsfield JL, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987; 2(8554): 291–3.
   Google Scholar
• Hendrix MG, Dormans PH, Kitslaar P, et al. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonatherosclerotic patients. Am J Pathol 1989; 134(5): 1151–7.
   Google Scholar
• Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311(7007): 711–4.
   Google Scholar
• Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71(5): 437–9.
   Google Scholar
• Folsom AR, Nieto FJ, Sorlie P, et al. Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators. Circulation 1998; 98(9): 845–50.
   Google Scholar
• Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. [Review] Blood Coagul Fibrinoly 1999; 10 (Suppl 1): S9–12.
   Google Scholar
• Ross R. Atherosclerosis—an inflammatory disease. New Engl J Med 1999; 340(2): 11526.
   Google Scholar
• Van Lente F. Markers of inflammation as predictors in cardiovascular disease. [Review] Clinica Chimica Acta 2000; 293(1-2): 31–52.
   Google Scholar
• Baumann H, Gauldie J. The acute phase response. [Review] Immunol Today 1994; 15(2): 74–80.
   Google Scholar
• Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144(6): 537–47.
   Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published erratum appears in N Engl J Med 1997 Jul 31; 337 (5):356]. N Engl J Med 1997; 336(14): 973–9.
   Google Scholar
• Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vascul Biol 1997; 17(6): 1121–7.
   Google Scholar
• Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279(18): 1477–82.
   Google Scholar
• Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99(2): 237–42.
   Google Scholar
• Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312(7038): 1061–5.
   Google Scholar
• Fyfe AI, Rothenberg LS, DeBeer FC, et al. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 1997; 96(9): 2914–9.
   Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98(9): 839–44.
   Google Scholar
• Rifai N. Joubran R. Yu H. Asmi M. Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem 1999; 45(11): 1967–73.
   Google Scholar
• Choudhury RP, Leyva F. C-Reactive protein, serum amyloid A protein, and coronary events [letter]. Circulation (Online) 1999; 100(15): e65–6.
   Google Scholar
• Pruzanski W, Stefanski E, de Beer FC, et al. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J Lipid Res 2000; 41(7): 1035–47.
   Google Scholar
• Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101(15): 1767–72.
   Google Scholar
• Biasucci LM. Vitelli A. Liuzzo G. Altamura S. Caligiuri G. Monaco C. Rebuzzi AG. Ciliberto G. Maseri A. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94(5): 874–7.
   Google Scholar
• Hasdai D, Scheinowitz M, Leibovitz E, et al. Increased serum concentrations of interleukin-1 beta in patients with coronary artery disease. Heart 1996; 76(1): 24–8.
   Google Scholar
• Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351(9096): 88–92.
   Google Scholar
• Rohde LE, Hennekens CH, Ridker PM. Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterio-scler Thromb Vascul Biol 1999; 19(7): 1595–9.
   Google Scholar
• de Lemos JA, Hennekens CH, Ridker PM. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol 2000; 36(2): 423–6.
   Google Scholar
• Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96(12): 4219–25.
   Google Scholar
• Wallen NH, Held C, Rehnqvist N, et al. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur Heart J 1999; 20(14): 103943.
   Google Scholar
• Blann AD, Seigneur M, Steiner M, et al. Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolaemia: relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events. Thromb Haemost 1998; 79(6): 1080–5.
   Google Scholar
• Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights from the Framingham Study. JAMA 1992; 267(9): 1253–1256.
   Google Scholar
• Gillum RF, Ingram DD, Makuc DM. White blood cell count and stroke incidence and death. The NHANES I epidemiologic follow-up study. Am J Epidemiol 1994; 139(9): 894–902.
   Google Scholar
• Sweetnam PM, Thomas HF, Yarnell JW, et al. Total and differential leukocyte counts as predictors of ischemic heart disease: the Caerphilly and Speedwell studies. Am J Epidemiol 1997; 145(5): 416–21.
   Google Scholar
• Bruno JJ. Inflammation, aspirin, and the risk of cardiovascular disease [letter]. New Engl J Med 1997; 337(6):422; discussion 423–4.
   Google Scholar
• Murray WM. Inflammation, aspirin, and the risk of cardiovascular disease [letter]. New Engl J Med 1997; 337(6):422; discussion 423–4.
   Google Scholar
• Feng D, Tracy RP, Lipinska I, et al. Effect of short-term aspirin use on C-reactive protein. J Thromb Thromboly 2000; 9(1): 37–41.
   Google Scholar
• Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an antiinflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000; 67(8): 863–76.
   Google Scholar
• Massy ZA, Kim Y, Guijarro C, et al. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun 2000; 267(2): 536–40.
   Google Scholar
• Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin [letter]. Lancet 1999; 353(9157): 983–4.
   Google Scholar
• Gurfinkel E, Bozovich G, Daroca A, et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350(9075): 404–7.
   Google Scholar
• Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999; 20(2): 121–7.
   Google Scholar
• Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96(2): 404–7.
   Google Scholar
• Dunne MW. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial. J Infect Dis 2000; 181 (Suppl 3): S572–8.
   Google Scholar
• Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100(1): 96–102.
   Google Scholar
• Wolbink GJ, Brouwer MC, Buysmann S, et al. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996; 157(1): 473–9.
   Google Scholar